What are the side effects of Ribociclib?

In clinical studies of Ribociclib (Ribociclib) in the treatment of breast cancer, the most common (≥20%) adverse reactions (including laboratory abnormalities) included leukopenia, neutropenia, hemoglobin decrease, lymphopenia, increased aspartate aminotransferase, increased gamma-glutamyl transferase, increased alanine aminotransferase, infection, nausea, increased creatinine, fatigue, thrombocytopenia, diarrhea, vomiting, headache, constipation, and alopecia.

Interstitial lung disease/Pneumonitis, serious skin adverse reactions, QT interval prolongation, hepatobiliary toxicity, neutropenia, embryo-fetal toxicity and other warnings and precautions were also found in clinical studies. Adverse events such as interstitial lung disease/pneumonitis, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS) have also occurred after Riboxil was put on the market. Riboxiclib should not be used in patients who are allergic to any ingredient or to peanuts or soybeans.

The original drug Riboxil has been launched in China, but due to its short time on the market, its price and purchase methods are not yet known, and it has not yet been included in the scope of medical insurance. The price of the European version of Riboxil's original drug, 200mg*21 tablets, sold overseas may be more than RMB 20,000 per box, while the Indian version of Riboxil's original drug, 200mg*21 tablets, may be priced around RMB 3,000 per box (the price may fluctuate due to exchange rates). The ingredients of the two drugs are basically the same. There are currently no generic versions of Riboxil produced and marketed.